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Abstract
Background: Children with chronic kidney disease (CKD) have increased cardiovascular mortality. Identifying high-risk
children who may benefit from further therapeutic intervention is difficult as cardiovascular abnormalities are subtle.
Although transthoracic echocardiography may be used to detect sub-clinical abnormalities, it has well-known problems
with reproducibility that limit its ability to accurately detect these changes. Cardiovascular magnetic resonance (CMR) is
the reference standard method for assessing blood flow, cardiac structure and function. Furthermore, recent innovations
enable the assessment of radial and longitudinal myocardial velocity, such that detection of sub-clinical changes is now
possible. Thus, CMR may be ideal for cardiovascular assessment in pediatric CKD. This study aims to comprehensively
assess cardiovascular function in pediatric CKD using CMR and determine its relationship with CKD severity.
Methods: A total of 120 children (40 mild, 40 moderate, 20 severe pre-dialysis CKD subjects and 20 healthy controls)
underwent CMR with non-invasive blood pressure (BP) measurements. Cardiovascular parameters measured included
systemic vascular resistance (SVR), total arterial compliance (TAC), left ventricular (LV) structure, ejection fraction (EF),
cardiac timings, radial and longitudinal systolic and diastolic myocardial velocities. Between group comparisons and
regression modelling were used to identify abnormalities in CKD and determine the effects of renal severity on
myocardial function.
Results: The elevation in mean BP in CKD was accompanied by significantly increased afterload (SVR), without evidence
of arterial stiffness (TAC) or increased fluid overload. Left ventricular volumes and global function were not abnormal in
CKD. However, there was evidence of LV remodelling, prolongation of isovolumic relaxation time and reduced systolic
and diastolic myocardial velocities.
Conclusion: Abnormal cardiovascular function is evident in pre-dialysis pediatric CKD. Novel CMR biomarkers may be
useful for the detection of subtle abnormalities in this population. Further studies are needed to determine to
prognostic value of these biomarkers.
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impairment
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Background
Cardiovascular events are a leading cause of death in
pediatric chronic kidney disease [1] (CKD). Two-
dimensional transthoracic echocardiography (TTE) is
conventionally used to assess the heart in children with
CKD. Several TTE markers have been used as indicators
of increased risk including: left ventricular (LV) hyper-
trophy (LVH), LV dysfunction and abnormal myocardial
strain [2–4]. However, TTE can be hampered by inaccur-
ate measurement of volumes and mass [5], as well as op-
erator dependence.
Cardiovascular magnetic resonance (CMR) cine im-
aging is the reference standard method of assessing LV
volumes, ejection fraction (EF) and mass [6]. Novel
CMR including tissue phase mapping (TPM) to assess
myocardial velocities [7] and high temporal resolution
phase contrast CMR (PCMR) to measure mitral inflow
velocities and cardiac timing intervals are also now avail-
able. Furthermore, CMR can be used to characterize the
vasculature by combining flow measurements with sim-
ultaneously acquired blood pressure (BP) [8]. Thus,
CMR offers a comprehensive method of assessing myo-
cardial and vascular phenotype in pediatric CKD.
The objectives of this study were to i) evaluate any differ-
ences in vascular and cardiac phenotype between healthy
children and those with CKD, ii) determine the relation-
ship between vascular and cardiac phenotype and any
additional effect of CKD, iii) assess the relationship be-




The study population consisted of 120 children: 100 with
confirmed CKD (stages 1–5) and 20 healthy volunteers.
The CKD patients were divided into 3 groups based on
CKD stage: Mild (CKD stage 1–2), Moderate (CKD stage
3) and Severe (CKD stage 4–5). The study was powered
to detect differences in mean arterial BP (MBP) between
the groups (including healthy controls). For between
group comparisons, a sample size of 14 children per
group provided 90% power (p < 0.05) to detect a differ-
ence of 3 mmHg in MBP (assuming a normal MBP of
82 mmHg, and a variance of 40 mmHg [9]). The group
size was increased to 20 for redundancy. In addition, we
increased the population size of the mild and moderate
CKD groups to 40 children in order to improve our
spread of estimated glomerular filtration rate (eGFR)
data points for correlation analysis.
All patients were recruited from the CKD and hyper-
tension clinics at Great Ormond Street Hospital,
London. Healthy subjects were recruited by advertising
within the hospital and a detailed history was taken from
the parents to ensure there was no significant medical
history. Exclusion criteria were: i) age < 7 or > 18 years,
ii) congenital structural heart disease or primary myocar-
dial disease, iii) primary renovascular disease, iv) active
vasculitis v) cardiac arrhythmia, vi) medical devices pre-
cluding CMR, vii) history of current or previous renal
replacement therapy and viii) acutely deteriorating renal
function. This study was approved by UK national re-
search ethics service (National Research Ethics Service
Committee London, London Bridge, reference: 15/LO/
0213). Informed parental consent and patient assent was
obtained from all participants.
All CKD participants had blood and urine tests as part
of their outpatient care including: haemoglobin (Hb),
urea, creatinine, electrolytes, calcium, phosphate, intact
parathyroid hormone level (PTH), and urine albumin to
creatinine ratio measurements. The eGFR was estimated
by modified Schwartz formula. Neither blood nor urine
tests were performed for healthy controls.
Imaging protocol
Imaging was performed on a 1.5 T CMR system
(Avanto; Siemens Healthineers, Erlangen, Germany) with
vector cardiographic gating. All CMR images were proc-
essed using in-house plug-ins developed for open-source
DICOM software OsiriX [10] (Osirix Foundation, Gen-
eva, Switzerland). All images were analyzed by the same
individual, who is a CMR trained cardiologist (MC) with
5 years of CMR experience. No gadolinium- contrast
was given.
Left ventricular volumes and mass
LV volumes were assessed using short axis multi-slice
free-breathing real-time radial k-t SENSE balanced
steady state free precision sequence sequence [11].
Scan parameters - FOV: ≈350 mm, matrix: 128 × 128,
voxel size: ≈2.7 × 2.7 × 8 mm, TE/TR: ≈1.1/ ≈2.2 msec,
Flip angle: 40°, acceleration factor: 8, temporal reso-
lution: ≈36 msec. LV endocardial borders were manu-
ally traced at end-diastole and end-systole to evaluate
end-diastolic volume (EDV) and end-systolic volume
(ESV). Stroke volume (SV) was obtained by subtract-
ing ESV from EDV. All ventricular volumes were
indexed to body surface area (BSA). LV EF was
assessed SV/LVEDV) × 100.
Epicardial LV borders were manually traced in end-
diastole and combined with endocardial borders to ob-
tain LV mass (LVM). The effect of body size on LV mass
was controlled by both indexing to height to the power
of 2.7 (LVMht2.7) [12] and dividing LVM by EDV to cal-
culate mass volume ratio (MVR) [13].
The right atrial and left atrial areas were measured in
diastole from 4-chamber view (using the same sequence)
and indexed to BSA.
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Cardiac timing and inflow velocities
LV outflow tract and mitral inflow velocities were assessed
with a free-breathing high temporal resolution real-time
UNFOLD-SENSE spiral PCMR sequence. This sequence
has previously been validated against Doppler echocardi-
ography [14]. Scan parameters - FOV: ≈450 mm, matrix:
128 × 128, voxel size: ≈3.5 × 3.5 × 7 mm, TE/TR: ≈1.97/
≈7.41 msec, flip angle: 20°, VENC: 150 m/s, acceleration
factor: 10, temporal resolution: ≈15 ms. The imaging plane
was positioned so that both the mitral inflow and LV out-
flow tract were imaged in the short axis.
The mitral valve orifice and LV outflow tract were
manually segmented from the resultant inflow and out-
flow curves to obtain the isovolumic relaxation time
(IRT), isovolumic contraction time (ICT) and ejection
time (ET) as previously described [14]. Myocardial per-
formance index (Tei) was calculated as the sum of ICT
and IRT divided by ET. Peak early (E) and atrial (A) dia-
stolic velocities were measured from the inflow curves.
Myocardial velocities
LV myocardial velocities was measured using a free breath-
ing self-navigated golden-angle spiral TPM sequence
planned in the mid LV short axis view [7, 15]. Scan param-
eters - FOV: ≈400 mm, matrix: 192 × 192, voxel size:
≈2.1 × 2.1 × 8 mm, TE/TR: ≈3.51/ ≈11.7 msec, flip angle:
15°, respiratory navigation efficiency: 30%, scan time: ≈7-
8 min, temporal resolution: ≈23 msec.
All TPM indices were measured from a mid LV short
axis slice. Each acquisition produces a magnitude image
and 3 phase images (in the x-, y- and z- direction). The
epi- and endocardial borders were manually segmented
on the magnitude image for all frames and regions of
interest were transferred to the accompanying phase im-
ages. From these masked phase images, radial velocity
was calculated by transforming the x and y-direction vel-
ocities to an internal polar coordinate system using the
LV center of mass as a reference point [7, 15]. The longi-
tudinal velocity was taken as the z-direction velocity.
Global radial and longitudinal LV velocities were calcu-
lated by averaging velocities across the segmented LV
slice for a given direction. The magnitude of the peak
systolic (S′), early diastolic (E’) and late diastolic (A’) vel-
ocities were measured from the velocity-time curves. E’/
A’ ratio was the ratio of longitudinal E’ over longitudinal
A’ velocity. The longitudinal E/E’ ratio was obtained by
dividing the mitral E wave velocity by longitudinal peak
early diastolic velocity.
Aortic flow
Aortic flow assessment was performed using a breath
held retrospectively-gated, spiral SENSE PCMR just
above the sinotubular junction [16]. Scan parameters -
FOV: ≈400 mm, matrix: 256 × 256, voxel size: ≈1.6 ×
1.6 × 5 mm, TE/TR: ≈2.1/≈8.0 msec, flip angle: 25°, ac-
celeration factor: 3, breath hold time: 4-8 s, temporal
resolution: ≈32.0 msec.
The aorta was segmented using a semi-automatic ves-
sel edge detection algorithm with manual operator cor-
rection. The SV was derived from the flow curve and
multiplied by heart rate to calculate cardiac output
(CO). The maximum (AoMax) and minimum (AoMin)
cross-sectional areas of the ascending aorta over the car-
diac cycle were also recorded.
Blood pressure measurement
Brachial systolic, diastolic and mean arterial BPs (SBP,
DBP, MBP) were measured using a CMR compatible
oscillometric sphygmomanometer (Datex Ohmeda; Gen-
eral Electric Healthcare, Boston, Massachusetts, USA)
during CMR image acquisition. This enabled optimum
combination of BP and flow data for calculation of vas-
cular indices. All BP measurements were acquired with
an appropriate sized arm cuff after the subject had been
lying in the scanner for at least 10 min. Pulse pressure
(PP) was the difference between SBP and DBP.
Measures of vascular characteristics
Total systemic vascular resistance (SVR) was calculated by
dividing MBP by cardiac output (CO) [8]. Total arterial
compliance (TAC) was calculated using a two-element
windkessel model described previously [8]. Briefly, aortic
flow curves were inputted into the model with measured
SVR. The compliance was tuned so that pulse pressure
generated by the model equaled measured pulse pressure.
Ascending aortic strain (AoS) was calculated as (AoMax –
AoMin)/AoMin (expressed as a percentage). Local arterial
stiffness was assessed by calculating ascending aortic com-
pliance (AoC) = AoS/pulse pressure [17].
Statistics
Statistical analyses were performed using Stata 13 (Stata-
Corp, College Station, Texas, USA). Data were examined
for normality using Shapiro-Wilk test and non-normally
distributed data was transformed using a zero-skewness
log transform prior to analysis. Descriptive statistics
were expressed as mean (± standard deviation) or geo-
metric mean (± geometric standard deviation) if data
was log transformed. Between CKD group differences
in vascular and cardiac phenotype were assessed using
analysis of variance (ANOVA) (objective 1). Levene’s
test was used to assess for homogeneity of variances
across the groups and Welch’s correction was applied
for non-homogeneous variance. Six groups of statistical
tests comparing healthy controls to patients were per-
formed in the following domains - baseline characteris-
tics, blood pressure, vascular phenotype, global cardiac
structure and function, cardiac timings and mitral
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velocities, and tissue phase mapping. Each group of
tests was considered a single family of statistical infer-
ences and the family-wise error rate was controlled
using Bonferroni correction. The corresponding cor-
rected critical p-values are listed in the respective ta-
bles. Post-hoc pairwise comparison was performed on
parameters significantly different on ANOVA testing.
The Bonferroni method was used to adjust for po-
tential Type 1 errors in the pairwise comparisons.
Spearman’s correlation coefficient (rho) was used to
determine the relationship between specific vascular
and cardiac phenotypic markers (objective 2) that
were significant on ANOVA testing. Multi-variable
ANOVA models were also constructed to examine
the independent effect of CKD group. Spearman’s
correlation coefficient was also used to determine
the relationship between markers of renal disease se-
verity - eGFR, hemoglobin (Hb) and PTH and significant
abnormal cardiac and vascular indices - MVR, IRT, S
′, E’, MBP, SVR (objective 3). Multi-variable linear
regression was used to determine the independent
effect of renal severity on cardiac markers by con-
trolling for vascular phenotype. Only patients with
recent blood tests were included into models involv-
ing blood indices. A p value < 0.05 was considered
statistically significant, except where Bonferroni cor-
rection was applied as indicated. Indices not statistically




The CKD cohort (n = 100) consisted of 40 children with
mild CKD (stage 1–2: eGFR 78.6 ± 8.8 ml/min/1.73 m2),
40 children with moderate CKD (stage 3: eGFR 48.3 ±
8.4 ml/min/1.73 m2) and 20 children with severe CKD
(eGFR 19.2 ± 6.5 ml/min/1.73 m2). Twenty-five (25%)
children (mild CKD: 10, moderate CKD: 9; severe CKD:
6) had a prior diagnosis of hypertension and were on
treatment (Table 1). The two most common causes of
CKD were congenital abnormalities of the kidney and
urinary tract (n = 60, 60%) and renal dysplasia (n =
11, 11%). All other causes represented < 10% of the
population. Eight CKD children had undergone a
previous nephrectomy. No children had previously
received or were currently receiving renal replacement
therapy as per exclusion criteria. None of the healthy
subjects (n = 20) had any significant past medical his-
tory nor were they taking any medications. There
were no differences in age, BSA or sex distribution
between groups (Table 1). As expected, markers of
renal function (urea, creatinine, eGFR and urine albu-
min/creatinine ratio) were worse in the latter CKD
stages, with the most abnormal results observed in










Age (years)a 12 ± 1.3 11 ± 1.3 12 ± 1.3 13 ± 1.3 0.12
Sex (% male) 40% 38% 23% 45% 0.42
Height (cm) 162 ± 18 150 ± 17 152 ± 18 151 ± 18 0.075
Weight (kg)a 53 ± 1.4 43 ± 1.5 45 ± 1.5 44 ± 1.4 0.22
Body Mass Index (kg/m2)a 20 ± 1.1 19 ± 1.2 20 ± 1.2 20 ± 1.1 0.77
Body Surface Area (m2) 1.6 ± 0.32 1.4 ± 0 .33 1.4 ± 0.35 1.4 ± 0.3 0.16
Hemoglobin (g/L) 132 ± 13 133 ± 16 128 ± 11 0.57
Urea (mmol/L) 5.4 ± 1.2 8.6 ± 2.5 18.0 ± 5.2 < 0.001†
Creatinine (umol/L)a 68 ± 1.2 117 ± 1.2 305 ± 1.4 < 0.001†
eGFR (ml/min/1.73 m2) 79 ± 8.8 48 ± 8.4 19 ± 6.5 < 0.001
Calcium-Phosphate product (mmol2/L2) 3.4 ± 0.45 3.4 ± 0.39 3.5 ± 0.56 0.40
Intact parathyroid hormone (pmol/L)a 3.5 ± 3.2 3.7 ± 2.4 8.5 ± 2.4 0.011
Urine Albumin/ Creatinine Ratio (mg/mmol)a 4.7 ± 3.7 22 ± 6.2 261 ± 2.5 < 0.001
Angiotensin converting enzyme inhibitor 28% 40% 15% 0.13
Calcium Channel Blocker 5% 13% 15% 0.38
Beta-Blocker 5% 5% 20% 0.09
Aldosterone antagonist (Spironolactone) 3% 0% 0% 0.47
Bonferroni correction applied- p < 0.003 is considered significant
Abbreviations: CKD chronic kidney disease, eGFR estimated globular filtration rate
aLogarithmic transformation was applied
†ANOVA Welch (W) test was used. 10% of CKD patients were on 2 or more anti-hypertensive agents
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the severe CKD group (p < 0.03). The severe CKD
group also had highest parathyroid hormone (PTH)
(p = 0.01). There was no difference in Hb between
the groups (p = 0.57). Outline of blood and urine tests re-
sults of study population can be seen in Additional file 1:
Table S1.
Vascular characteristics
The DBP, DBP centile and MBP were significantly differ-
ent between the groups (p < 0.001, Table 2) and were
elevated in all CKD groups compared to controls (p <
0.05) on pairwise comparison. However, there were no
significant differences between the CKD groups. There
were also no group differences in SBP and PP (p ≥ 0.13),
although there was a trend for SBP centile (p = 0.08).
The SVR was also significantly different between the
groups (p = 0.004, Table 3). On pairwise comparison,
both moderate and severe CKD groups were elevated
compared to controls (p ≤ 0.014). However, there were
no significant differences in SVR between the CKD
groups. Importantly, there were no group differences in
TAC, local measures of ascending aorta stiffness (AoS
and AoC) or cardiac output (Table 3).
Cardiac geometry and global function
There was a significant difference in MVR (a marker of
LV remodeling) between the groups (p = 0.003, Table 4).
On pairwise comparison, only the severe CKD group
was significantly different from healthy subjects and all
other CKD groups (p ≤ 0.034).
The MVR correlated with all measures of BP (SBP: rho
= 0.29, p = 0.001; MBP: rho = 0.26, p = 0.004; and DBP:
rho = 0.19, p = 0.036; Fig. 1). When a model was created
to study the combined effect of BP and CKD group on LV
remodeling, both SBP (BP with highest univariate correl-
ation) and CKD group were independent predictors of
MVR (p = 0.009, p = 0.008 respectively).
The SVR correlated with MVR (rho = 0.3, p < 0.001), and
remained an independent predictor of MVR (p < 0.001) in
a model including CKD group (p = 0.01). There was no cor-
relation between MVR and TAC (p = 0.15). Although
LVMht2.7 did appear higher in CKD, this did not reach stat-
istical significance (p = 0.12, Table 4).
There were no differences in EDV, ESV, SV, EF, RAA
or LAA between the groups (Table 4).
Inflow velocities and cardiac timing intervals
The IRT (a marker of active myocardial relaxation [18])
was different across groups (p < 0.001, Table 5). On pair-
wise comparison, IRT was significantly elevated in mod-
erate and severe CKD patients compared to controls
(p ≤ 0.01). In addition, IRT was higher in severe CKD
than in mild CKD patients (p = 0.023).
There was a significant association between IRTand MVR
(rho = 0.25, p = 0.008) as seen in Fig. 1. However, both MVR
and CKD group were independent predictors of IRT in a
multi-variable model (p = 0.01 and 0.007 respectively).
There were no differences in ICT, ET or Tei index
between the groups. Peak transmitral E and A wave vel-
ocities and peak E/A ratio were also normal in CKD
(Table 5).
Tissue phase mapping
Radial S′ velocity, a marker of systolic function, was sig-
nificantly different between groups (p = 0.003, Table 6).
Specifically, radial S′ was lower in moderate and severe
CKD compared to controls (p ≤ 0.035). There was no
significant difference in longitudinal S′ between groups.
Radial S′ negatively correlated with MBP (rho = − 0.22,
p = 0.016), DBP (rho = − 0.37, p < 0.0001–Fig. 2) and
SVR (rho = − 0.22, p = 0.014), but not SBP (p = 0.52).
Longitudinal S′ did not significantly correlate with any
blood pressures. A model created to study the effects of
CKD and DBP (BP with highest univariate correlation)
on radial systolic velocity demonstrated that DBP was an
independent predictor of radial S′ (p = 0.001) but CKD
group was not significant (p = 0.16). Radial S′ also sig-
nificantly correlated with LVEF (rho = 0.24, p = 0.009-










Systolic BP (mmhg)a 109 ± 1.1 113 ± 1.1 116 ± 1.1 116 ± 1.1 0.14
Systolic BP percentilea 33 ± 2.5 58 ± 1.7 61 ± 1.8 64 ± 1.7 0.08†
Diastolic BP (mmhg)a 53 ± 1.2 63 ± 1.2 65 ± 1.2 69 ± 1.2 < 0.001
Diastolic BP percentilea 17 ± 2.3 45 ± 1.9 48 ± 1.8 60 ± 1.6 < 0.001†
Mean BP (mmhg) 78 ± 7.8 84 ± 8.8 87 ± 9.9 89 ± 8.8 < 0.001
Pulse Pressure (mmhg) 55 ± 13 50 ± 10 51 ± 9.5 48 ± 12 0.13
Heart Rate (BPM)a 72 ± 1.2 75 ± 1.2 72 ± 1.2 74 ± 1.2 0.75
Bonferroni correction applied- p < 0.007 is considered significant
Abbreviations: CKD chronic kidney disease, BP blood pressure, BPM beats per minute
aLogarithmic transformation was applied
†ANOVA Welch (W) test was used
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Fig. 2), but there was no association between LVEF and
longitudinal S′ (p = 0.24).
Radial E’ velocity, a marker of LV relaxation and stiff-
ness, was significantly lower in all CKD groups com-
pared to controls (p ≤ 0.005) on pairwise comparison.
However, there were no significant differences between
the CKD groups. There were no significant group differ-
ences in longitudinal E’ velocity in CKD (Table 6). Radial E’
was negatively correlated with DBP (rho = − 0.21, p = 0.021)
and SVR (rho = − 0.27, p = 0.003). Two separate models
were created to separately study the effects of CKD and
DBP or SVR on radial E’. Although CKD group and SVR
were independent determinants of Radial E’ (p < 0.003
and 0.01, respectively), DBP was not a significant pre-
dictor (p = 0.19).
In addition, radial and longitudinal E’ correlated nega-
tively with IRT (rho = − 0.28, p < 0.003 & rho = − 0.24,
p < 0.01 respectively). Unlike IRT, neither was associated
with MVR or LVMht2.7 (p > 0.25).
The E’/A’ was different between groups (p = 0.003,
Table 6), but was only significantly reduced in moderate
CKD compared to controls and mild CKD (p ≤ 0.035)
on pairwise comparison. There were no group differ-
ences in radial and longitudinal A’ velocities or E/E’.
Association between renal and cardiovascular biomarkers
Worsening eGFR was associated with higher MBP
(rho = − 0.26, p = 0.04), MVR (rho = − 0.29, p = 0.02) and
longer IRT (rho = − 0.30, p = 0.02). On multi-variable re-
gression, eGFR remained a significant determinant of
MVR (β = − 0.26, p = 0.035,) and IRT (β = − 0.28, p =
0.043) after adjustment for MBP (p ≥ 0.06). In a model
with IRT as dependant variable, eGFR trended towards
significant (β = − 0.25, p = 0.052) and MVR was significant
(β = 0.27, p = 0.039).
Reduced Hb was also associated with a reduced radial
function (Rad S′: rho = 0.35, p < 0.005, Rad E’: rho =
0.35, p < 0.006). These relationships remained significant
after adjusting for the effect of afterload (MBP or SVR)
in a multi-variable regression model (Rad S′ models: Hb
p = 0.001, Rad E’ models: Hb p = 0.001). There were no
other significant relationships between eGFR, PTH and
Hb with other cardiovascular parameters.










SVR (WU.m2)a 21 ± 1.3 24 ± 1.2 26 ± 1.2 26 ± 1.2 0.004
TAC (ml/mmHg. m2.102)a 52 ± 1.3 55 ± 1.2 54 ± 1.3 58 ± 1.3 0.56
AoS (%)a 46 ± 1.5 52 ± 1.6 53 ± 1.6 51 ± 1.5 0.74
AoC (%mmHg−1.102)a 86 ± 1.6 108 ± 1.6 105 ± 1.7 111 ± 1.7 0.33
COa (l/min/m2) 3.6 ± 1.2 3.5 ± 1.2 3.4 ± 1.2 3.4 ± 1.2 0.61
Bonferroni correction applied- p < 0.01 is considered significant
Abbreviations: CKD chronic kidney disease, SVR systemic vascular resistance, TAC total arterial compliance. AoS ascending aortic strain, AoC ascending aortic
compliance, CO cardiac output
aLogarithmic transformation was applied










LVEDV (ml/m2) 74 ± 11 68 ± 9.1 68 ± 10 65 ± 9.7 0.03
LVESV (ml/m2)a 23 ± 1.3 21 ± 1.3 20 ± 1.3 19 ± 1.3 0.13
LVSV (ml/m2)a 50 ± 1.1 46 ± 1.1 47 ± 1.2 46 ± 1.2 0.18
EF (%) 68 ± 4.6 68 ± 6.1 69 ± 6.7 70 ± 5.8 0.72
LVMht2.7 (g/m2.7)a 21 ± 1.2 21 ± 1.3 22 ± 1.2 25 ± 1.2 0.12
MVR (g/ml) 0.7 ± 0.1 0.72 ± 0.16 0.75 ± 0.16 0.87 ± 0.17 0.003
RA Area (cm2/m2) 12 ± 1.8 12 ± 1.9 11 ± 2.5 11 ± 2 0.69
LA Area (cm2/m2)a 12 ± 1.3 12 ± 1.2 11 ± 1.2 11 ± 1.2 0.38
Bonferroni correction applied- p < 0.006 is considered significant
Abbreviations: CKD chronic kidney disease, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVSV left ventricular stroke
volume, EF ejection fraction, LVMht(2.7) left ventricular mass indexed to height to the power of 2.7, MVR left ventricular mass to volume ratio
aLogarithmic transformation was applied
Cheang et al. Journal of Cardiovascular Magnetic Resonance  (2018) 20:24 Page 6 of 11
Discussion
This is the largest study to investigate the vascular
and cardiac phenotype in pre-dialysis pediatric CKD
using CMR. The main findings were that children
with CKD had: i) elevated BP (both MBP and DBP),
ii) increased SVR, but no evidence of increased vas-
cular stiffness, iii) higher LV MVR independent of
BP, iv) abnormalities of diastolic function suggestive
of reduced active relaxation and increased chamber
stiffness and v) Reduced systolic velocities with pre-
served global systolic function. These changes ap-
peared most marked in children with moderate and
severe CKD stages.
Vascular phenotype in pediatric CKD
It is well recognized that hypertension is common in
pediatric CKD [19]. However, the abnormal components
of afterload have not been fully described. In this study,
we found that SVR was significantly increased in all
CKD groups compared to normal controls. Possible
reasons include; salt retention and abnormal renin-
angiotensin stimulation [20], sympathetic overdrive [21]
and endothelial dysfunction via reduced nitric oxide bio-
availability [22]. Irrespective of the cause, our results
suggest that vascular resistance is an important mediator
of increased afterload and may be a useful target for
intervention. Interestingly, we found no evidence of
reduced TAC or increased aortic stiffness. This is
slightly surprising as studies have shown elevated
pulse wave velocity (PWV), reduced carotid distensi-
bility and increased carotid intimal medial thickness
in children with CKD [23]. However, elevated PWV
is not a universal finding and even in positive stud-
ies, PWV is only mildly raised (i.e. in the 4C’s study
the PWV z-score was 0.33) [23]. Furthermore,
changes in carotid artery characteristics do not
necessarily reflect changes in the aorta [24], which is
the repository for most vascular buffering. In fact,
pulse pressure has been shown to be normal in other
large pediatric CKD studies [25], which is in keeping
with our finding of normal aortic stiffness. Of course,
the vascular phenotype may be different in dialysis
patients due to more extensive arterial calcification.
Other possible causes of hypertension in CKD are
fluid overload or high CO. Although fluid overload is
difficult to assess, we did show that RAA (a marker
of fluid overload) was normal in our cohort. Further-
more, we also demonstrated that CO was not
increased in CKD. Therefore, it is unlikely that these
factors are important in the pathogenesis of hyperten-
sion in early CKD.
Left ventricular remodelling in CKD
In our study, we demonstrated that children in the se-
verest CKD group had increased LV MVR compared to
controls and, as eGFR fell, MVR increased. These results
suggest that worsening CKD is associated with increased
concentric remodelling in children. Interestingly, height
indexed LV mass was not statistically different in our
Fig. 1 a & b: Relationship between mass volume ratio (MVR) and
cardiovascular characteristics - a. MVR versus systolic blood pressure
(SBP) (rho = 0.29, p = 0.001), b. MVR versus isovolumic relaxation time
(IRT) (rho = 0.25, p = 0.008). The 95% confidence interval of the
predicted mean is illustrated by grey zone










IRT (ms)a 61 ± 1.2 64 ± 1.1 70 ± 1.1 72 ± 1.1 < 0.001
ICT (ms)a 44 ± 1.6 36 ± 1.6 33 ± 1.8 37 ± 1.8 0.24
ET (ms) 277 ± 21 275 ± 16 274 ± 19 276 ± 15 0.92
Teia 0.39 ± 1.3 0.37 ± 1.2 0.38 ± 1.2 0.41 ± 1.3 0.56
E (mls) 47 ± 9.8 49 ± 11 50 ± 11 49 ± 9.7 0.87
A (mls) 19 ± 4.3 20 ± 6.7 21 ± 6.8 22 ± 5.6 0.36
E/A ratioa 2.6 ± 1.2 2.6 ± 1.4 2.5 ± 1.5 2.3 ± 1.3 0.63
Bonferroni correction applied- p < 0.007 is considered significant
Abbreviations: CKD chronic kidney disease, IRT isovolumic relaxation time, ICT isovolumic contraction time, ET ejection time, Tei myocardial performance index,
E early transmitral mean velocity, A late transmitral mean velocity, E/A ratio E to A ratio
aLogarithmic transformation was applied
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population, unlike previous TTE studies. This may be
due to the well-recognized overestimation of LV mass
using TTE, particularly in patients with CKD [26].
Ventricular remodelling in these children is partly ex-
plained by their hypertensive phenotype. However, both
CKD group and eGFR remained significant predictors of
MVR after controlling for BP. This implies that other
‘uremic’ processes are involved in CKD associated remod-
elling. Possible ‘uremic’ causes of hypertrophy include:
anemia, hyperparathyroidism and sympathetic overactivity
[24, 27, 28]. Identification of the exact stimulus may pro-
vide new targets for therapeutic intervention that may be
important in remediating the increased cardiovascular risk
associated with LVH [2].
Diastolic function in CKD
We found conventional transmitral inflow peak E/A to
be normal in children with CKD. However, both IRT and
radial E’ were abnormal, pointing towards subtle dia-
stolic dysfunction in moderate to severe CKD. In
addition, longer IRT was associated with lower eGFR.
IRT is a marker of active myocardial relaxation and cor-
relates with invasively measured isovolumic relaxation
constant [18]. Previous studies in adults have shown that
active relaxation is associated with LV mass [29] and our
findings are in keeping with this. However, even after
controlling for MVR, CKD remains a significant
predictor of IRT and eGFR trends towards significance.
This suggests that CKD exerts an independent effect
possibly mediated through abnormal energy or calcium
handling. This could be due to myocyte/capillary mis-
match resulting in a relative oxygen deficit as demon-
strated in animal models [30].
Early diastolic peak velocity is a marker of both active
relaxation and ventricular compliance [31]. Our demon-
stration of lower E’, measured using TPM, is in keeping
with a previous smaller study in pediatric CKD [32]. In
our study, E’ did not correlate with MVR or LVMht2.7.
Thus, reduced early filling cannot simply be explained by
LV hypertrophy. One explanation for reduced ventricular
compliance is myocardial fibrosis, which has been demon-
strated in several animal models [33]. Unfortunately, it is
not possible to perform post contrast T1 mapping in these
patients due to the risk of nephrogenic systemic fibrosis
[34]. Nevertheless, non-contrast methods are now avail-
able [34] and these could be used to quantify fibrosis in
future studies. We also demonstrated that lower radial E’
was associated with lower Hb. The reason for this is un-
clear but may be related to reduced oxygen delivery affect-
ing the active component of relaxation.
Systolic function in CKD
Global systolic function was preserved in CKD
patients with normal LVEF. However, radial S′ was
reduced in moderate and severe CKD, implying some










Rad S′ (cm/s) 2.7 ± 0.31 2.6 ± 0.24 2.5 ± 0.38 2.4 ± 0.31 0.003
Rad E’ (cm/s) 4.2 ± 0.59 3.6 ± 0.62 3.4 ± 0.78 3.3 ± 0.53 < 0.001
Rad A’ (cm/s) 1.3 ± 0.35 1.1 ± 0.34 1.2 ± 0.31 1.2 ± 0.28 0.30
Long S′ (cm/s) 4.6 ± 1.6 3.9 ± 1.1 3.4 ± 1.3 3.6 ± 1.3 0.009
Long E’ (cm/s) 7.9 ± 1.5 7.5 ± 2.0 6.7 ± 1.8 6.8 ± 1.4 0.046
Long A’ (cm/s) 2.3 ± 0.71 2.5 ± 1.1 2.7 ± 0.85 2.5 ± 0.64 0.61
Long E’/A’ ratioa 3.4 ± 1.3 3.2 ± 1.6 2.6 ± 1.4 2.8 ± 1.3 0.003†
Long E/E’ ratioa 6 ± 1.2 6.7 ± 1.3 7.5 ± 1.4 7.3 ± 1.4 0.03
Bonferroni correction applied- p < 0.006 is considered significant
Abbreviations: CKD chronic kidney disease, Rad radial, Long longitudinal, S′ systolic myocardial velocity, E’ early diastolic myocardial velocity, A’ late diastolic
myocardial velocity, E’/A’ E’ over A’ ratio, E/E’ E over E’ ratio
aLogarithmic transformation was applied
†ANOVA Welch (W) test was used
Fig. 2 a & b: Relationship between tissue phase mapping indices
and conventional measures of cardiac function - a. Radial systolic
myocardial velocity (S′) versus diastolic blood pressure (DBP)
(rho = − 0.37, p < 0.0001), b. Radial systolic myocardial velocity (S′)
versus ejection function (rho = 0.24, p = 0.009). The 95% confidence
interval of the predicted mean is illustrated by the grey zone
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element of systolic dysfunction in the latter stages of
renal disease. These findings are in keeping with pre-
vious tissue Doppler imaging and echocardiographic
strain studies and illustrate the importance of asses-
sing systolic function in a more sophisticated manner
[4, 35]. The most obvious explanation for reduced S′
is that increased blood pressure limits contraction
through the force velocity relationship. This is in
keeping with our findings in which DBP independ-
ently predicted radial S′, unlike CKD group.
The use of CMR for cardiovascular assessment in CKD
We have demonstrated that children with CKD exhibit a
specific, but subtle cardiovascular phenotype. This
phenotype is characterized by: i) increased MVR, ii) in-
creased IRT, iv) reduced radial S′ and E’ and iv) in-
creased SVR. All of these metrics can be evaluated with
TTE. In fact, due to its high temporal resolution, it is
probably the most accurate method of assessing timing
parameters (i.e. IRT) and tissue velocity. However, there
are some limitations to TTE. In particular, TTE overesti-
mates LVM [26] and cannot accurately estimate CO (ne-
cessary for calculation of SVR). As we have found that
these two measures are abnormal in pediatric CKD, we
believe there may be a role for CMR identification of ab-
normal cardiac and vascular phenotypes in this group of
patients. Nevertheless, it is still unclear what the clinical
significance of this phenotype is. The next important
step is to ascertain whether it can be used to guide ther-
apy and determine prognosis.
Limitations
An important limitation is the relatively older age of the
study cohort. Although the entire cohort of CKD
patients did include patients from 7 to 18 years of age,
the majority of children were between the ages of 9 to
16 years. Thus, the study findings may not be as applic-
able to younger children. In order to ensure that the
study findings can be extrapolated to all age groups, fu-
ture studies should consider recruiting younger patients.
The absence of recent TTE data in the subjects is also
a potential limitation in this study. Performing an TTE
in tandem may have been informative for the compari-
son of CMR findings with an established standard clin-
ical investigation. This would have enabled us to
confirm our CMR findings of subtle systolic and dia-
stolic impairment with TTE results. Unfortunately, this
was not performed as part of the study protocol in order
to minimise inconvenience to the study subjects. No re-
cent clinical TTE data were available for comparison in
this cohort either. However, despite that, our findings
are in agreement with the majority of previous studies in
pediatric CKD using TTE as referenced in the paper.
Another limitation is our use of mild, moderate and
severe CKD grouping instead of the conventional
categorization of CKD stages 1–5. This was done to en-
sure adequate powering for group wise differences.
However, the use of conventional CKD groups would be
desirable in future larger, multicenter studies.
Finally, BP measurements were carried out using an
oscillometric sphygmomanometer, which may be less ac-
curate than using manual sphygmomanometer [36]. This
was because it was essential for BP measurements to be
acquired simultaneously during PCMR flow acquisition
for accurate assessment of vascular measures. Unfortu-
nately, this could not be performed manually in the
CMR scanner during flows acquisitions. However, BP
measurement was taken with a standardized protocol for
all subjects using the same machine. This meant that the
measurements were comparable across the cohort.
Conclusion
It is possible to use CMR to comprehensively evaluate
cardiac and vascular phenotype in children with CKD.
In the future, these novel CMR indices may even be use-
ful for identifying high-risk pediatric CKD patients.
More work is needed to determine normative pediatric
values. Future prospective studies will also be required
to correlate these markers with prognosis in order to
predict cardiovascular risk.
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